CQP(SZ:000950)2025-06-10 09:06Group 1: Financial Performance - In Q1 2025, the company achieved a revenue growth of 17% in medical devices and 10% in professional pharmacy (DTP) sales [2] - The total revenue from the traditional Chinese medicine sector reached 14.86 billion CNY in 2024, with over 140 subsidiaries involved in this business [5] Group 2: Strategic Developments - The company has established partnerships with over 400 medical institutions under the General Group, opening accounts in 102 of them, including 86 grade hospitals [2] - The "300 Cities" strategic plan has been implemented, covering 160 cities across 31 provinces and regions in China [4] Group 3: Future Plans - The company aims to deepen its investment and acquisition efforts in 2025 to strengthen its regional network and enhance competitive advantages [4] - Future developments in the traditional Chinese medicine sector will focus on building a comprehensive industry chain, including smart Chinese medicine pharmacies and specialty Chinese medicine pieces [5] Group 4: Marketing and Sales Initiatives - The company has formed a national marketing team to enhance service capabilities, achieving sales in 31 provinces through its CSO projects [6] - New product promotions have been successfully launched, including several proprietary drugs [6]